Full Product Name
MYH3 siRNA (Rat)
Product Synonym Names
Myosin-3; Myosin heavy chain 3; Myosin heavy chain. fast skeletal muscle. embryonic
Product Gene Name
MYH3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P12847
Specificity
MYH3 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat MYH3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of MYH3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MYH3 sirna
siRNA to inhibit MYH3 expression using RNA interference
Applications Tested/Suitable for MYH3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for MYH3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_036736.1
[Other Products]
NCBI GenBank Nucleotide #
NM_012604.1
[Other Products]
UniProt Primary Accession #
P12847
[Other Products]
UniProt Related Accession #
P12847[Other Products]
Molecular Weight
223,858 Da
NCBI Official Full Name
myosin-3
NCBI Official Synonym Full Names
myosin, heavy chain 3, skeletal muscle, embryonic
NCBI Official Symbol
Myh3??[Similar Products]
NCBI Official Synonym Symbols
Myhse; RNMHCG
??[Similar Products]
NCBI Protein Information
myosin-3
UniProt Protein Name
Myosin-3
UniProt Synonym Protein Names
Myosin heavy chain 3; Myosin heavy chain, fast skeletal muscle, embryonic
UniProt Gene Name
Myh3??[Similar Products]
UniProt Entry Name
MYH3_RAT
NCBI Summary for MYH3
heavy chain of myosin; involved in muscle contraction [RGD, Feb 2006]
UniProt Comments for MYH3
MYH3: Muscle contraction. Defects in MYH3 are the cause of distal arthrogryposis type 2A (DA2A); also known as Freeman-Sheldon syndrome (FSS). Distal arthrogryposis is a clinically and genetically heterogeneous group of disorders characterized by bone anomalies and joint contractures of the hands and feet, causing medially overlapping fingers, clenched fists, ulnar deviation of fingers, camptodactyly and positional foot deformities. It is a disorder of primary limb malformation without primary neurologic or muscle disease. DA2A is the most severe form of distal arthrogryposis. Affected individuals have contractures of the orofacial muscles, characterized by microstomia with pouting lips, H-shaped dimpling of the chin, deep nasolabial folds, and blepharophimosis. Dysphagia, failure to thrive, growth deficit, and life-threatening respiratory complications (caused by structural anomalies of the oropharynx and upper airways) are frequent. Inheritance is autosomal dominant. Defects in MYH3 are the cause of distal arthrogryposis type 2B (DA2B); also known as Sheldon-Hall syndrome (SHS) or arthrogryposis multiplex congenita distal type 2B (AMCD2B). DA2B is a form of inherited multiple congenital contractures. Affected individuals have vertical talus, ulnar deviation in the hands, severe camptodactyly, and a distinctive face characterized by a triangular shape, prominent nasolabial folds, small mouth and a prominent chin. DA2B is the most common of the distal arthrogryposis syndromes. It is similar to DA2A but the facial contractures are less dramatic.
Protein type: Motility/polarity/chemotaxis; Motor
Cellular Component: myofibril; contractile fiber; myosin complex
Molecular Function: actin filament binding; calmodulin binding; microfilament motor activity; motor activity; actin binding; ATP binding
Biological Process: skeletal muscle contraction; metabolic process
Research Articles on MYH3
1. IGF1 downregulates embryonic myosin heavy chain in myoblast nuclei [embryonic myosin heavy chain (eMyHC)]
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
